W.K. (Bill) Rader
President and CEO
Mr. Rader is a serial entrepreneur who sold his first company at age 18. To date he has launched five ventures and orchestrated multiple M&A's. Mr. Rader founded Efferent Labs, Inc. in 2011 with a passion derived from his personal experience. He created Efferent on the shoulders of a company he founded in 1998 and successfully exited in 2015, Raland Technologies (now Raland Compliance Partners). Mr. Rader grew Raland from a one-man startup to an Inc. 500|5000 company with a global footprint and 4 divisions. While leading Raland, he established strategic office locations and provided services to clients including Fortune 500 pharmaceutical, biotech and medical device companies throughout the United States, Europe and Asia. His efforts enabled Raland to become one of the most highly respected and sought after providers within the Life Science industry.
Mr. Rader started his career in the engineering sector of the U.S. Navy as a Nuclear Engineering Reactor Controls member of the Submarine Fleet. He holds a Bachelor of Science in Electrical Engineering, is a member of Harvard Business School, Business Innovations in Global Healthcare class of 2015, and a graduate of the University at Buffalo, School of Management. Mr. Rader is a NYBio Fellow, and a member of many industry organizations including ISPE, PDA, IEEE, MedTech, Tech Council/MDBio, and ISA.
Spencer Z. Rosero, MD
Chief Medical Officer
Dr. Rosero serves as the Chief Medical Officer of Efferent Labs, Inc., working with the Scientific Advisors and directing discovery activity.
Dr. Rosero is Associate Professor of Medicine and Director, Cardiology Clinical Research at the University of Rochester School of Medicine and Dentistry where he also serves as Clinical Director at the Center for Medical Technology and Innovation. He is a practicing cardiologist who has developed the CytoComm™ technology through years of work with patients. As a specialist in heart rhythm disorders, Dr. Rosero treats patients using a wide range of therapeutic options, including radiofrequency ablation of abnormal rhythms, implantation of electronic medical devices such as pacemakers, defibrilllators (ICD's), and cardiac resynchronization therapy devices. He is an experienced clinical investigator and has actively participated in several large multicenter trials studying the role of medical devices in treating patients with heart failure and life threatening arrhythmias. As the site principal investigator for the early evaluation of a novel implantable left atrial pressure monitoring system at the University of Rochester, Dr. Rosero's team was the first in the nation to implant the St. Jude Heart Pod device. His research interests include living cell embedded biosensors, hereditary arrhythmias, and futuristic medical device technologies that support personalization of medical care.
Chief Financial Officer
Mr. Greco, an entrepreneur and venture advisor and founder of Cupule Ventures, provides venture development and support to early stage Biotech, Life Science, Material Science and Technology companies, concentrated across Upstate New York. Taking a hands-on role, Greco manages executive, financial and operational functions, as his efforts have centered in formation, management, fundraising and growing commercial operations. Instrumental in the launching and growth of 20+ start-ups, primarily of higher technology or advance manufacturing pedigrees, Greco managed the investment efforts of 10+ successful private placements and managed several acquisitions, domestic and international.
Previous to founding Cupule, Greco was a Venture Associate on two funds with Trillium Group, LLC, in Rochester, NY, eclipsing $135M in investments and has deep entrepreneurial roots of his own, starting his first company in 2003. He has an M.B.A. from the Simon School of Business Administration and a B.A. in Economics from the University of Rochester.
Vice President and Director of Data Science
Mr. Baldwin launched his first company shortly after completing his undergraduate curriculum. His partners included Rochester Regional Health and the University of Rochester Medical Center. This is where he learned how to fulfill data and security needs to meet rapidly changing rules and regulations.
In addition to healthcare consulting he also supported two other early-stage ventures. As part of this effort he was accepted into the High Tech Rochester LaunchPad software accelerator and received the Global Entrepreneurship Week Top 50 award presented by the Kaufmann Foundation.
Prior to Efferent he joined a high-growth VC backed startup where he contributed to business intelligence and predictive analytics. The company raised $50M across three rounds of funding, saw 500% growth in employee headcount and 700% growth in sales in less than 18 months.
He received a B.S. in Bioengineering and B.A. in Philosophy from Binghamton University. While a student research assistant he was invited to present his research titled “Control of AV Nodal Excitation during Atrial Fibrillation” at the National Conference on Undergraduate Research.